- Home
- MYD vs SIGA Comparison
MYD vs SIGA Comparison
Compare MYD & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYD
- SIGA
- Stock Information
- Founded
- MYD 1991
- SIGA 1995
- Country
- MYD United States
- SIGA United States
- Employees
- MYD N/A
- SIGA N/A
- Industry
- MYD Investment Bankers/Brokers/Service
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- MYD Finance
- SIGA Health Care
- Exchange
- MYD Nasdaq
- SIGA Nasdaq
- Market Cap
- MYD 523.6M
- SIGA 551.0M
- IPO Year
- MYD N/A
- SIGA 1997
- Fundamental
- Price
- MYD $10.38
- SIGA $5.94
- Analyst Decision
- MYD
- SIGA
- Analyst Count
- MYD 0
- SIGA 0
- Target Price
- MYD N/A
- SIGA N/A
- AVG Volume (30 Days)
- MYD 253.1K
- SIGA 567.4K
- Earning Date
- MYD 01-01-0001
- SIGA 11-07-2024
- Dividend Yield
- MYD 4.55%
- SIGA 10.15%
- EPS Growth
- MYD N/A
- SIGA N/A
- EPS
- MYD N/A
- SIGA 1.20
- Revenue
- MYD N/A
- SIGA $173,731,386.00
- Revenue This Year
- MYD N/A
- SIGA $16.79
- Revenue Next Year
- MYD N/A
- SIGA $15.08
- P/E Ratio
- MYD N/A
- SIGA $4.94
- Revenue Growth
- MYD N/A
- SIGA 399.31
- 52 Week Low
- MYD $8.76
- SIGA $4.26
- 52 Week High
- MYD $11.30
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- MYD 19.14
- SIGA 38.74
- Support Level
- MYD $11.16
- SIGA $5.62
- Resistance Level
- MYD $11.44
- SIGA $6.23
- Average True Range (ATR)
- MYD 0.14
- SIGA 0.43
- MACD
- MYD -0.10
- SIGA -0.07
- Stochastic Oscillator
- MYD 8.20
- SIGA 19.02
About MYD Blackrock MuniYield Fund Inc.
Blackrock Muniyield Fund Inc is a non-diversified, closed-end management investment company. The fund's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.